Media coverage
13
Media coverage
Title Eolas Therapeutics Announce Initiation of a Phase I Clinical... Media name/outlet San Francisco Chronicle Country/Territory United States Date 5/12/19 URL https://www.sfgate.com/business/press-releases/article/Eolas-Therapeutics-Announce-Initiation-of-a-Phase-14882636.php Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet Spoke.com Country/Territory United States Date 5/12/19 URL www.spoke.com/press_releases/5de84ae93433271306015100 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet ProfitQuotes.com Country/Territory United States Date 5/12/19 URL www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=201912201912041810PR_NEWS_USPR_____UN57263 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for... Media name/outlet PRWeb Country/Territory United States Date 4/12/19 URL https://www.prweb.com/releases/eolas_therapeutics_announce_initiation_of_a_phase_i_clinical_trial_for_azd4041_an_orexin_1_receptor_antagonist_for_smoking_cessation/prweb16766973.htm Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet PRWeb Country/Territory United States Date 4/12/19 URL https://www.prweb.com/releases/eolas_therapeutics_announce_initiation_of_a_phase_i_clinical_trial_for_azd4041_an_orexin_1_receptor_antagonist_for_smoking_cessation/prweb16766973.htm Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation; Eolas Therapeutics Inc. today announced the initiation of a Phase I study of AZD4041 for treating tobacco use and depend Media name/outlet PR Newswire Country/Territory United States Date 4/12/19 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet Bio-Medicine Country/Territory United States Date 4/12/19 URL www.bio-medicine.org/medicine-news-1/Eolas-Therapeutics-Announce-Initiation-of-a-Phase-I-Clinical-Trial-for-AZD4041--an-Orexin-1-Receptor-Antagonist-for-Smoking-Cessation-167530-1/ Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet Finanzen.ch Country/Territory Switzerland Date 4/12/19 URL https://www.finanzen.ch/nachrichten/aktien/eolas-therapeutics-announce-initiation-of-a-phase-i-clinical-trial-for-azd4041-an-orexin-1-receptor-antagonist-for-smoking-cessation-1028738853 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet SSUChronicle.com Country/Territory United States Date 4/12/19 URL https://www.ssuchronicle.com/2019/12/04/eolas-therapeutics-announce-initiation-of-a-phase-i-clinical-trial-for-azd4041-an-orexin-1-receptor-antagonist-for-smoking-cessation/ Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Pha Media name/outlet ADVFN Deutschland Country/Territory Germany Date 4/12/19 URL de.advfn.com/p.php?pid=nmona&article=81286572 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet TickerTech.com Country/Territory United States Date 4/12/19 URL www.tickertech.com/cgi/?a=news&ticker=a&w=&story=201912201912041810PR_NEWS_USPR_____UN57263 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet Markets Business Insider Country/Territory United States Date 4/12/19 URL www.quotenet.com/news/stocks/eolas-therapeutics-announce-initiation-of-a-phase-i-clinical-trial-for-azd4041-an-orexin-1-receptor-antagonist-for-smoking-cessation-1028738853 Persons Paul Kenny Title Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation Media name/outlet BizWire Express Country/Territory India Date 4/12/19 URL www.bizwireexpress.com/showstoryPRWeb.php?storyid=708472 Persons Paul Kenny